Resources
42 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/15/2024 (updated 5/23/2024)
The 2024 RCORP Data Coordinator meeting series began in May 2024, hosted by RCORP-Evaluation (Customer Value Partners), in partnership with RCORP-TA (JBS International). The purpose of this meeting series is to present a deep dive into all aspects of PIMS data collection with an overview of data requirements, data collection, and addressing common data collection challenges with hands-on best practices. This series is geared towards Data Coordinators; however, anyone involved in RCORP grant data collection is welcome to join. You can find slides, recordings, and materials from the meetings linked below.
Posted 2/14/2023 (updated 4/15/2024)
The RCORP Data Coordinator meeting series began in July 2022, hosted by RCORP-Evaluation in partnership with RCORP-TA. These meetings provide an opportunity for the JBS RCORP team to work with Data Coordinators and other consortium staff to address topics impacting data quality, reporting and utilization. Discussion in these meetings helps to inform additional webinar sessions and resources, developed to meet grantee needs.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 4/1/2021 (updated 4/5/2024)
This webinar will provide an overview of COVID-19 impacts and vaccination attitudes among SUD populations in Vermont including people who use drugs, patients receiving MAT, and people in recovery. It will outline the methods undertaken to conduct a community-based survey. It will discuss the barriers and opportunities that arose from analysis of the survey and a subsequent consortium workshop.
Posted 2/17/2021 (updated 4/4/2024)
People suffering from addiction or people who are in recovery from the condition, face a variety of challenges, including, in many cases, in their interactions with health-care services. Many of these challenges may be attributed to the stigma that still clings unhelpfully to addiction. It may also be due to a surprising lack of awareness even among health-care professionals about the nature of addiction and the susceptibilities and anxieties of those initiating or attempting to sustain recovery.
This review and report is a starting point, an attempt to get a handle on the state of play and the issues that need addressing when it comes to pain management in people with current or past addictions. It helps to identify gaps in knowledge, understanding, skill, practice and culture, pointing the way to how these deficiencies might be remedied.
Posted 9/29/2021 (updated 4/3/2024)
In this re-welcome session, HRSA Project Officers shared reminders and updates about grant deliverables, the Evaluation Team will gave updates, and Technical Expert Leads discussed new and ongoing technical assistance available to Implementation I, Implementation II and MAT-Expansion grantees.
Posted 11/11/2021 (updated 4/3/2024)
Performance Improvement Measurement System
Posted 11/9/2021 (updated 4/3/2024)
This workshop will explore the link between Adverse Childhood Experiences (ACEs) of individuals with substance use concerns and its impact on their development. We will explore the experiences, perceptions, beliefs, and behaviors that may present challenges in development. We will discuss practical, trauma-informed, outcome-driven strategies that improve the outcomes.
Posted 10/14/2021 (updated 4/3/2024)
Representatives from the JBS/HRSA evaluation team presented information on Performance Improvement Measurement System deliverables and answer grantee questions.
Rebecca Schachtner, PhD, JBS International
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.